[HTML] springer.comFull View

[HTML][HTML] Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study

F Azribi, E Abdou, E Dawoud, M Ashour, A Kamal… - BMC cancer, 2021 - Springer
Background Patients with pathogenic sequence variants (PSVs) in BRCA1/BRCA2 are at
high risk of developing ovarian cancer (OC). However, genetic testing for BRCA1/BRCA2 …
被引用次数：8 相关文章

Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study

F Azribi, E Abdou, E Dawoud, M Ashour… - BMC …, 2021 - squ.elsevierpure.com
Background: Patients with pathogenic sequence variants (PSVs) in BRCA1/BRCA2 are at
high risk of developing ovarian cancer (OC). However, genetic testing for BRCA1/BRCA2 …
[HTML] biomedcentral.com

[HTML][HTML] Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study

F Azribi, E Abdou, E Dawoud, M Ashour… - BMC …, 2021 - bmccancer.biomedcentral.com
Patients with pathogenic sequence variants (PSVs) in BRCA1/BRCA2 are at high risk of
developing ovarian cancer (OC). However, genetic testing for BRCA1/BRCA2 PSVs is still …

Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.

F Azribi, E Abdou, E Dawoud, M Ashour, A Kamal… - BMC Cancer, 2021 - go.gale.com
Background Patients with pathogenic sequence variants (PSVs) in BRCA1/BRCA2 are at
high risk of developing ovarian cancer (OC). However, genetic testing for BRCA1/BRCA2 …

Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study

F Azribi, E Abdou, E Dawoud, M Ashour… - BMC …, 2021 - search.proquest.com
Background Patients with pathogenic sequence variants (PSVs) in BRCA1/BRCA2 are at
high risk of developing ovarian cancer (OC). However, genetic testing for BRCA1/BRCA2 …

Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.

F Azribi, E Abdou, E Dawoud, M Ashour, A Kamal… - BMC Cancer, 2021 - europepmc.org
Background Patients with pathogenic sequence variants (PSVs) in BRCA1/BRCA2 are at
high risk of developing ovarian cancer (OC). However, genetic testing for BRCA1/BRCA2 …
[HTML] nih.gov

[HTML][HTML] Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study

F Azribi, E Abdou, E Dawoud, M Ashour, A Kamal… - BMC Cancer, 2021 - ncbi.nlm.nih.gov
Background Patients with pathogenic sequence variants (PSVs) in BRCA1/BRCA2 are at
high risk of developing ovarian cancer (OC). However, genetic testing for BRCA1/BRCA2 …

Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study

F Azribi, E Abdou, E Dawoud, M Ashour… - BMC …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Patients with pathogenic sequence variants (PSVs) in BRCA1/BRCA2 are at
high risk of developing ovarian cancer (OC). However, genetic testing for BRCA1/BRCA2 …

Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study

F Azribi, E Abdou, E Dawoud, M Ashour… - BMC …, 2021 - nchr.elsevierpure.com
Background: Patients with pathogenic sequence variants (PSVs) in BRCA1/BRCA2 are at
high risk of developing ovarian cancer (OC). However, genetic testing for BRCA1/BRCA2 …
[PDF] biomedcentral.com

[PDF][PDF] Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study

F Azribi, E Abdou, E Dawoud, M Ashour, A Kamal… - 2021 - bmccancer.biomedcentral.com
Background: Patients with pathogenic sequence variants (PSVs) in BRCA1/BRCA2 are at
high risk of developing ovarian cancer (OC). However, genetic testing for BRCA1/BRCA2 …